Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Bostwick

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Pathology|December 9, 2023
Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patientsHemamali Samaratunga, Lars Egevad, John Yaxley, et al.
BJU International|January 14, 2012
Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancerStephen Langley, Hashim U Ahmed, Bashar Al-Qaisieh, et al.
Journal of Endourology|April 2, 2005
Smooth-muscle regeneration after electrosurgical endopyelotomy in a porcine model as confirmed by electron microscopyJamil Rehman, Maged M Ragab, Ramakrishna Venkatesh, et al.
Plant Cell Reports|December 18, 2007
Isolation and characterization of a molecule stimulatory to growth of somatic embryos from early stage female gametophyte tissue of loblolly pineVeronica De Silva, David Bostwick, Kristi L Burns, et al.
Cancer Detection and Prevention|November 3, 2006
Precancer: a conceptual working definition -- results of a Consensus ConferenceJules J Berman, Jorge Albores-Saavedra, David Bostwick, et al.
The Journal of Urology|November 16, 2010
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE studyGerald L Andriole, David Bostwick, Otis W Brawley, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Pathology|December 9, 2023
Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patientsHemamali Samaratunga, Lars Egevad, John Yaxley, et al.
BJU International|January 14, 2012
Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancerStephen Langley, Hashim U Ahmed, Bashar Al-Qaisieh, et al.
Journal of Endourology|April 2, 2005
Smooth-muscle regeneration after electrosurgical endopyelotomy in a porcine model as confirmed by electron microscopyJamil Rehman, Maged M Ragab, Ramakrishna Venkatesh, et al.
Plant Cell Reports|December 18, 2007
Isolation and characterization of a molecule stimulatory to growth of somatic embryos from early stage female gametophyte tissue of loblolly pineVeronica De Silva, David Bostwick, Kristi L Burns, et al.
Cancer Detection and Prevention|November 3, 2006
Precancer: a conceptual working definition -- results of a Consensus ConferenceJules J Berman, Jorge Albores-Saavedra, David Bostwick, et al.
The Journal of Urology|November 16, 2010
The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE studyGerald L Andriole, David Bostwick, Otis W Brawley, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Pageof 2